Multiple antidiabetic formulary alternatives available: metformin, meglitinides (repaglinide, nateglinide), DPP4i's. (Januvia, Tradjenta), GLP1RAs (Trulicity
by HT Ou 2024 Cited by 30In April 2024, the US Food and Drug Administration (FDA) warned of the potentially increased risk of HF with the use of two DPP4i drugs –
by O Varpuluoma 2024 Cited by 49the association between DPP4i medication use and. BP risk.5-7 Currently, it is not known whether DPP4i- associated BP is a drug-induced or
by M Chadha 2024 Cited by 28Studies with SGLT2i agents as well as DPP4i agents suggest that these drugs have beneficial effects on TIR. DPP4i fixed-drug combination.
Add further oral drugs from choice of sulfonylurea, pioglitazone, DPP4i (gliptin) or SGLT2i. GLP-1. If HbA1c≥ . If BMI 35, consider replacing one of three
by A Gravani 2024 Cited by 1Medications in patients with DPP4i associated bullous pemphigoid and in patients without BP despite DPP4i use. Medication. Cohort, n (%) p. OR
GLP-1 RA is added as a third drug to metformin and OADs like SU, DPP4i and pioglitazone if glycaemic target is not achieved at 6 months with OADs (metformin, SU, DPP4i and pioglitazone) and lifestyle modifications GLP-1 RA is considered as an add-on to insulin regimen if glycaemic target is not achieved at 9 months
DPP4i allows better glycemic control than starting low-dose gliclazide Drugs for Type 2 Diabetes in a Real-world Setting in the Middle East
Patients taking dipeptidyl peptidase4 drugs (DPP4i)a Type 2 diabetes drughad an incidence of acute pancreatitis recurrence of 23.3% versus
Comments